Atropine vs Isoprenaline in the Invasive Diagnosis of Arrhythmias
Launched by MEDICAL UNIVERSITY OF LODZ · Oct 9, 2023
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how two different medications, atropine and isoprenaline, can help doctors better diagnose heart rhythm problems, specifically arrhythmias. During a special test called an electrophysiological study (EPS), these medications are used to see how the heart conducts electrical signals. The goal is to find out which medication provides better information for doctors and helps improve patient outcomes.
To participate in this study, patients must be between 65 and 74 years old and have been recommended for an EPS according to heart health guidelines. However, individuals who have certain heart conditions, like previous episodes of serious arrhythmias or glaucoma (which is a condition that makes atropine unsuitable), cannot take part. While the study is not yet recruiting participants, those who join can expect to receive one of the two medications during their heart study, helping researchers understand which might be more effective for diagnosing heart issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with indication for electrophysiological study according to present guidelines of European Society of Cardiology
- Exclusion Criteria:
- • Not willing or incapable to give written informed consent.
- • Previous diagnosed ventricle tachycardia or fibrillation
- • Previous diagnosed atrial fibrillation or flutter
- • Glaucoma (contraindication for atropine)
About Medical University Of Lodz
The Medical University of Lodz is a leading academic institution dedicated to advancing healthcare through innovative research and clinical trials. With a strong focus on medical education, the university fosters collaboration among healthcare professionals, researchers, and students to enhance clinical practices and patient outcomes. Its commitment to excellence in scientific inquiry and patient care positions it as a pivotal sponsor of clinical trials, aimed at translating research findings into practical applications that benefit diverse populations. Through rigorous methodologies and ethical standards, the Medical University of Lodz contributes significantly to the global medical community and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lodz, Poland
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported